Study identifies new molecular target for treating deadly lung disease IPF

April 10, 2018, Cincinnati Children's Hospital Medical Center
In this microscopic photo of tissue from mouse lung with idiopathic pulmonary fibrosis (IPF), extensive fibrosis and collagen deposits (shown in red) have extensively infiltrated the tissue. Researchers at Cincinnati Children's report in Cell Reports that loss of the gene Foxf1 in lung myofibroblasts increased the severity of IPF in mice. Credit: Cincinnati Children's

Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.

A research team at Cincinnati Children's Hospital Medical Center reports its data in the journal Cell Reports. It found that a gene called FOXF1 inhibits the IPF disease process, which includes extensive scarring in lung connective tissues, hyper-production of harmful cells called myofibroblasts and excessive lung inflammation.

Their data show human lungs from IPF patients and mouse models of IPF lack FOXF1 in myofibroblasts. But cells lacking FOXF1 also exhibit overexpression of a related gene called FOXM1, which drives lung scarring and inflammation.

"The exact cause of IPF is unknown and effective treatments are needed. This study identifies a novel anti-fibrotic drug target that inhibits pulmonary fibrosis in our preclinical models," said lead investigator Tanya Kalin, MD, PhD, Division of Pulmonary Biology. "We are developing different therapeutic approaches and conducting preclinical tests to increase FOXF1 expression in the cells of connective tissues."

Although Kalin stressed that an estimated two to three years of additional laboratory study and development are needed before it's known if the data can be applied to clinical treatment, the research team is working on several potential therapeutic tools to boost FOXF1 levels in IPF. This includes testing a novel small-molecule compound that stabilizes FOXF1 and inhibits myofibroblasts in IPF. Researchers also are testing a nanoparticle-based gene delivery method to get FOXF1 into lungs with IPS.

Untangling a Mystery

FOXF1 is a transcription factor—a regulator gene that essentially tells other what to do, including what proteins to make and biological processes to help initiate or inhibit. The current study shows FOXF1 is supposed to act as a molecular switch for two other genes called cadherins (CDH2 and CDH11).

FOXF1 induces CDH2, but inhibits CDH11 to shut down IPF if something triggers it. Researchers performed extensive lab and genetic analyses on biopsied human lungs donated by IPF patients and mouse models of IPF to find out that when FOXF1 is repressed its sister gene FOXM1 increases and fuels the disease.

IPF's precise causes remain unknown, but genetic predisposition, smoking and other potential environmental factors are suspected. Also under investigation are the effects these factors may have on human epigenetics—how environment changes regulate the activity of our genes.

To induce and study the IPF disease process in laboratory mice, the rodents were administered a chemotherapy agent for treating certain cancers called bleomycin. The chemical is toxic to the respiratory system and triggered tissue damage and fibrotic scarring in the animals' lungs. Human IPF biopsy samples were also used in these studies.

According to the National Library of Medicine at the National Institutes of Health (NIH), IPF usually affects people between the ages of 50 and 70, but it can strike younger adults and children. About 100,000 people are affected in the United States, with an estimated 30,000 to 40,000 new cases diagnosed annually.

The most common signs and symptoms of the disease are shortness of breath and a persistent dry, hacking cough.

Explore further: Scientists propose treatment for severe lung diseases

Related Stories

Scientists propose treatment for severe lung diseases

April 19, 2016
Researchers are developing a new drug to treat life-threatening lung damage and breathing problems in people with severe infections like pneumonia, those undergoing certain cancer treatments and premature infants with underdeveloped, ...

Restoring lipid synthesis could reduce lung fibrosis

March 6, 2018
Pulmonary fibrosis, an ongoing process of scarring that leaves patients chronically short of breath, can progress in severity until the only course of treatment is lung transplant. A new study shows that restoring the lipids ...

Pulmonary fibrosis caused by single transcription factor

December 26, 2017
To date, the molecular basis of pulmonary fibrosis has been poorly understood. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now shown that reduced activity of the transcription ...

Experimental drug targets nucleus of allergen-sensitized cells

April 18, 2017
Transcription factors, the tiny proteins that switch genes on or off in the nucleus of cells, are considered unreachable molecular targets for drugs attempting to treat medical conditions. Overcoming this challenge, researchers ...

Radiation and pulmonary fibrosis

November 16, 2017
Radiation-induced pulmonary fibrosis—tissue scarring that can permanently impair lung function—limits the delivery of therapeutic radiation doses to non-small cell lung cancer.

Thyroid hormone therapy heals lung fibrosis in animal study

December 4, 2017
Thyroid hormone therapy significantly resolves fibrosis, or scarring, in the lungs of mice, increasing their survival from disease, a Yale-led study shows. These provide a novel insight into the development of pulmonary fibrosis ...

Recommended for you

Gene plays critical role in noise-induced deafness

October 19, 2018
In experiments using mice, a team of UC San Francisco researchers has discovered a gene that plays an essential role in noise-induced deafness. Remarkably, by administering an experimental chemical—identified in a separate ...

Scientists grow functioning human neural networks in 3-D from stem cells

October 18, 2018
A team of Tufts University-led researchers has developed three-dimensional (3-D) human tissue culture models for the central nervous system that mimic structural and functional features of the brain and demonstrate neural ...

Functional engineered oesophagus could pave way for clinical trials 

October 18, 2018
The world's first functional oesophagus engineered from stem cells has been grown and successfully transplanted into mice, as part of a pioneering new study led by UCL.

New findings cast light on lymphatic system, key player in human health

October 16, 2018
Scientists at the Oklahoma Medical Research Foundation have broken new ground in understanding how the lymphatic system works, potentially opening the door for future therapies.

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Age-related increase in estrogen may cause common men's hernia

October 16, 2018
An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery, according to a Northwestern Medicine study was published Oct. 15 ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.